Merck 2Q Revenues: $5.8 billion (+6%) 2Q Earnings: $1.5 billion (+108%)* YTD Reveneus: $11.2 billion (+3%) YTD Earnings: $3 billion (+44%) Comments: Zocor sales were $990 million, down 14% due to loss of marketing exclusivity. Singulair sales reached $950 million, up 30%. Rotateq sales were $31 million for the quarter. The Merck/Schering-Plough partnership reported global sales of Zetia and Vytorin reached $973 million as compared to $507 million in 2Q2005. R&D expenses w...